0.33 USD
▼-0.11-24.49%
盘后 0.60 0.00%
2026-11-20
市值
$13.57M
市盈率
0.30
EPS
1.11
股息率
—
52 周区间
0.30 – 2.44
成交量
70.95K
Beta
-0.13
目标价
—
52W 低 0.3052W 高 2.44
价格走势
公司简介
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropen...